DaVita vs Tenet Healthcare: Strategic Comparison
Direct Answer
Tenet Healthcare is the bigger company by revenue: $21.31 billion in 2025 net operating revenues versus DaVita's $13.643 billion, both for the fiscal year ended December 31, 2025. Tenet also employed more people, about 99,000 against DaVita's 78,000. DaVita is the more concentrated business, almost entirely dialysis, while Tenet spreads revenue across acute-care hospitals, the USPI ambulatory surgery network and Conifer revenue-cycle services. On profit margin, Tenet's 2025 net income of $1.407 billion was helped by one-time items, while DaVita's $746.8 million came from a steadier, treatment-based business.
DaVita and Tenet Healthcare both sell into the same U.S. health-insurance system but barely compete for the same patient: DaVita runs the dialysis chair, Tenet runs the hospital and the surgery center down the street. DaVita, which traces back to a 1979 dialysis business later renamed from Total Renal Care in 2000, reported $13.643 billion in 2025 revenue and $746.8 million of net income attributable to the company, with about 78,000 employees. Tenet, whose roots go back to National Medical Enterprises in 1969, reported $21.31 billion in 2025 net operating revenues and $1.407 billion of net income available to common shareholders, with about 99,000 employees. Javier J. Rodriguez has run DaVita since June 1, 2019, while Saum Sutaria, M.D. has been Tenet's Chairman and CEO since September 1, 2021.
Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.
Key Differences at a Glance
| Field | DaVita Inc. | Tenet Healthcare Corporation |
|---|---|---|
| Latest annual revenue | $13.6B (FY2025) | $21.3B (FY2025) |
| Founded | 1979 | 1969 |
| Employees | 78,000 | 99,000 |
| Market Cap | $12.4B | $17.2B |
| Headquarters | United States | United States |
| Revenue / Employee | $175k / employee | $215k / employee |
| Valuation Multiple | 0.9x P/S | 0.8x P/S |
Strategic Positioning
Business model and competitive context from the cited profiles
DaVita Inc. Strategic Vector
FY2025 Revenue BaselineDaVita's earnings depend more on payer mix and cost per treatment than on patient volume. With U.S. volume roughly flat, buybacks and rate increases drove Q2 2026 EPS up 36% year over year. That gives Berkshire's ~45% stake, capped by agreement, an unusual role in its capital allocation.
Tenet Healthcare Corporation Strategic Vector
FY2025 Revenue BaselineTenet Healthcare Corporation's long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward secular migration of complex procedures to outpatient ascs, where the Centers for Medicare and Medicaid Services (CMS) continues to reclassify increasingly complex surgical procedures, such as total joint replacements and advanced spinal fusions, as eligible for outpatient reimbursement, creating a multi-year runway for Tenet's USPI platform to capture high-margin volume migrating out of the traditional inpatient hospital setting. Concurrently, the organization focuses on navigating market pressures around aggressive managed care denial tactics and prior authorization, addressing environments where dominant commercial health plans and Medicare Advantage insurers are increasingly utilizing advanced AI-driven prior authorization and denial management tactics to shift financial risk back onto hospitals, systematically compressing Tenet's operating margins and increasing the administrative burden and bad debt exposure across its Hospital Operations segment. By maintaining disciplined capital allocation and operational rigor, Tenet Healthcare Corporation aims to protect its unit economics and preserve its economic moat across changing market cycles.
Quick Stats Comparison
| Metric | DaVita Inc. | Tenet Healthcare Corporation |
|---|---|---|
| Revenue | $13.6B (FY2025) | $21.3B (FY2025) |
| Founded | 1979 | 1969 |
| Headquarters | Denver, Colorado | Dallas, Texas |
| Market Cap | $12.4B | $17.2B |
| Employees | 78,000 | 99,000 |
| Revenue / Employee | $175k / employee | $215k / employee |
| Valuation Multiple | 0.9x P/S | 0.8x P/S |
DaVita Revenue vs Tenet Healthcare Revenue — Year by Year
| Year | DaVita Inc. | Tenet Healthcare Corporation | Higher reported revenue |
|---|---|---|---|
| 2025 | $13.6B | $21.3B | Tenet Healthcare Corporation (approx. USD) |
| 2024 | $12.8B | $20.7B | Tenet Healthcare Corporation (approx. USD) |
| 2023 | $12.1B | $20.6B | Tenet Healthcare Corporation (approx. USD) |
| 2022 | $11.6B | $19.2B | Tenet Healthcare Corporation (approx. USD) |
| 2021 | $11.6B | $19.5B | Tenet Healthcare Corporation (approx. USD) |
Business Model Breakdown
Overview: DaVita Inc. vs Tenet Healthcare Corporation
This in-depth comparison examines DaVita Inc. and Tenet Healthcare Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching DaVita Inc. on its own, evaluating Tenet Healthcare Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between DaVita Inc. and Tenet Healthcare Corporation is widest.
On the headline numbers, annual revenue is $13.6B (FY2025) for DaVita Inc. and $21.3B (FY2025) for Tenet Healthcare Corporation, while their respective market capitalizations stand at $12.4B and $17.2B. Both DaVita Inc. and Tenet Healthcare Corporation are headquartered in United States. Their local markets and applicable rules may still differ.
DaVita Inc.: DaVita is a Denver-based kidney care provider and a member of the S&P 500. It offers in-center hemodialysis, home peritoneal dialysis and home hemodialysis, hospital inpatient dialysis, and care management for chronic kidney disease. At June 30, 2026 it served about 298,500 patients at 3,266 outpatient centers worldwide. CEO Javier J. Rodriguez has led the company since 2019, and Berkshire Hathaway, its largest shareholder since first buying in 2011, owns about 45%. The company is headquartered in Denver, Colorado.
Tenet Healthcare Corporation: Tenet Healthcare's official story is about 50 acute care hospitals and more than 500 ambulatory surgery centers generating $20.68 billion in fiscal 2024 revenue. The real story is more specific: a company that inherited the wreckage of Oral Roberts' failed $80 million City of Faith medical center, survived a $900 million Medicare fraud settlement in 2006, and has since rebuilt itself into a business whose most valuable asset is a revenue cycle management subsidiary most people have never heard of. The 99,000 employees spread across 30 states handle 4.2 million inpatient admissions annually. That is the visible operation. The less visible operation is Conifer Health Solutions, a revenue cycle management subsidiary that reduced internal days in accounts receivable to 48 days in fiscal 2024, meaningfully below the industry average of 54 days, by deploying AI-driven patient engagement software that processes claims faster than competitors' systems. The hospital segment achieved a 12.8% adjusted EBITDA margin in fiscal 2024, which management directly attributed to cutting contract labor costs by 45% compared to the fiscal 2022 peak. The travel nurse crisis that inflated labor costs across the industry hit Tenet hard, the company's response was to invest in permanent staffing infrastructure rather than continue paying premium rates to temporary contract workers. Revenue has grown from $19.1 billion in fiscal 2022 to $20.68 billion in fiscal 2024, a steady increase that reflects both the ambulatory surgery center expansion and the USPI segment's 6.5% same-facility revenue growth driven by high-acuity orthopedic and gastroenterology procedures. The company has also retired more than $4 billion in debt since 2020, reducing its leverage ratio to 2.1x. The company is headquartered in Dallas, Texas.
Business Models: How DaVita Inc. and Tenet Healthcare Corporation Make Money
DaVita Inc. and Tenet Healthcare Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between DaVita Inc. and Tenet Healthcare Corporation.
DaVita Inc. business model: DaVita is paid per dialysis treatment. Most patients receive in-center hemodialysis about three times a week, while others dialyze at home with DaVita training and support. Medicare's bundled ESRD payment covers the majority of patients, but commercial insurers pay substantially more per treatment, so payer mix is the key profit driver. In Q2 2026 U.S. revenue per treatment was $415.87 against patient care costs of $277.40. Many clinics are joint ventures with nephrology practices, and the Integrated Kidney Care (IKC) unit takes risk-based contracts, including the CMS Kidney Care Choices model, where DaVita shares in savings when total cost of care falls.
Tenet Healthcare Corporation business model: Conifer's business model is scalable, relying on a combination of long-term, multi-year enterprise contracts, performance-based fee structures (where Conifer takes a percentage of the additional revenue it recovers for the client), and the licensing of its proprietary analytics and patient engagement software platforms. Every 1% increase in the company's reliance on contract labor translates to tens of millions of dollars in incremental annualized expense, a cost that cannot be immediately passed through to fixed-fee Medicare reimbursement rates or fully recovered in commercial payer negotiations that are locked into multi-year contracts. Finally, the macroeconomic environment of elevated interest rates has significantly increased the cost of refinancing Tenet's substantial long-term debt load, meaning that even as the company pays down principal, the interest expense associated with its remaining variable-rate facilities and upcoming maturities continues to consume a significant portion of its operating cash flow, restricting the capital available for dividend payments, share buybacks, or aggressive M&A expansion in the fragmented ASC market. The company's geographic footprint provides a third layer of competitive defense, as Tenet has concentrated its hospital and ASC assets in high-growth, high-managed-care-penetration markets in the Sun Belt, specifically Florida, Texas, Arizona, and the Carolinas, where demographic tailwinds, favorable regulatory environments, and a concentration of commercially insured patients provide a structural pricing advantage over competitors burdened by legacy facilities in declining, unionized, or Medicaid-dominant markets in the Northeast and Midwest. Concurrently Tenet is betting on the transition from fee-for-service reimbursement to value-based care contracts, using its Conifer Health Solutions analytics platform and its network of employed and affiliated physicians to build the population health management infrastructure required to assume downside financial risk for the total cost of care for millions of Medicare Advantage and commercially insured lives.
Competitive Advantage: DaVita Inc. vs Tenet Healthcare Corporation
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of DaVita Inc. stack up against those of Tenet Healthcare Corporation.
DaVita Inc. competitive advantage: DaVita's advantages are scale and operating discipline. Its dense U.S. network of 2,671 clinics, long-standing nephrologist joint ventures, purchasing scale, and experience with Medicare billing and quality programs are hard for new entrants to copy. Recurring treatment schedules create predictable demand, which supports steady free cash flow ($1.024 billion in 2025) and large share buybacks.
Tenet Healthcare Corporation competitive advantage: Tenet's advantage is scale across about 50 acute care hospitals, 275 urgent care and occupational health centers, and more than 500 ambulatory surgery centers, which gives it weight when negotiating reimbursement with commercial insurers. Its Conifer Health Solutions subsidiary processes billions of dollars of claims a year for Tenet and for outside health systems, which helps Tenet manage insurer denials and earns service revenue from other hospital groups.
Growth Strategy: Where DaVita Inc. and Tenet Healthcare Corporation Are Headed
Future prospects matter as much as current results. The growth strategies below explain how DaVita Inc. and Tenet Healthcare Corporation each plan to expand from here.
DaVita Inc. growth strategy: DaVita's strategy is to grow earnings faster than revenue. It raises revenue per treatment, controls patient care costs, and buys back shares with free cash flow. It also expands international clinics (595 centers in 14 countries by mid-2026), grows home dialysis, and scales Integrated Kidney Care risk contracts that pay for slowing disease progression and reducing hospitalizations. Through Mozarc Medical, its kidney-technology joint venture with Medtronic, it invests in new dialysis devices.
Tenet Healthcare Corporation growth strategy: Tenet's strategy is to move with the shift of care from hospitals to outpatient settings. Its United Surgical Partners International (USPI) business operates more than 500 ambulatory surgery centers and 31 surgical hospitals across 29 states, mostly through joint ventures with local physicians, and it accounts for a growing share of the company's EBITDA. In hospitals, Tenet focuses on markets with favorable demographics and a strong commercial payer mix, and on treating higher-acuity patients rather than adding beds. Under CEO Saum Sutaria the company has moved from debt-funded acquisitions to debt reduction, margin improvement and outpatient growth.
Financial Picture: DaVita Inc. vs Tenet Healthcare Corporation
A closer look at the financial trajectory of DaVita Inc. and Tenet Healthcare Corporation rounds out the comparison.
DaVita Inc.: DaVita reported 2025 revenue of $13.643 billion (up 6.5% from $12.816 billion in 2024), operating income of $2.044 billion, and net income attributable to DaVita of $747 million. Adjusted diluted EPS from continuing operations was $10.78. Operating cash flow was $1.887 billion and free cash flow $1.024 billion, and the company repurchased 12.7 million shares at an average $140.09. In Q2 2026 revenue reached $3.554 billion, operating income $579 million (16.3% margin), and diluted EPS $4.02. DaVita guides to 2026 adjusted EPS of $14.10 to $15.20 and free cash flow of $1.0 to $1.25 billion. It pays no dividend and returns cash through buybacks. DaVita Inc. is a massive healthcare provider focused on kidney care, maintaining a market valuation generally over $10 billion.
Tenet Healthcare Corporation: Tenet Healthcare reported 2025 net operating revenues of $21.31 billion, up 3.1% from $20.675 billion in 2024, with consolidated adjusted EBITDA of $4.566 billion (21.4% margin). Net income available to common shareholders was $1.407 billion ($15.49 per diluted share), versus $3.2 billion in 2024, when results were inflated by gains on hospital divestitures. Momentum continued in 2026: second-quarter revenue rose 6.8% to $5.628 billion, adjusted EBITDA grew 16.3% to $1.304 billion (23.2% margin), and hospital-segment EBITDA margin improved to 18.0%. Management raised 2026 guidance to $21.9-$22.5 billion of revenue and $4.83-$5.03 billion of adjusted EBITDA, and the board added $2.0 billion to the share buyback authorization.
Company-Specific SWOT Notes
DaVita Inc.
DaVita and Fresenius Medical Care serve the large majority of U.S. dialysis patients.
Commercial insurers cover a small minority of DaVita's U.S. patients but pay several times Medicare rates, so they produce a disproportionate share of profit.
Because commercial patients drive so much profit, small shifts in payer mix, such as patients moving from commercial plans to Medicare, can swing earnings noticeably from quarter to quarter.
DaVita runs with high leverage to fund buybacks and keeps net leverage around 3x adjusted EBITDA.
Integrated Kidney Care turned profitable in 2025, and management expected about $20 million of additional IKC operating income in 2026.
CMS sets the ESRD bundled payment each year, and updates often trail labor and supply cost inflation.
Tenet Healthcare Corporation
Tenet's USPI platform operates more than 500 ambulatory surgery centers primarily through joint ventures where referring physicians hold 15-40% equity stakes, structurally locking in patient referral networks and creating an unreplicable competitive moat that
Tenet reported 2025 net operating revenues of $21.31 billion, up 3.1%, with consolidated adjusted EBITDA of $4.566 billion, a 21.4% margin.
Despite strategic optimization, Tenet's hospital network still maintains a higher percentage of Medicaid and uninsured patients in key urban markets compared to HCA Healthcare, resulting in lower average reimbursement rates and higher exposure to uncompensated
The decisive, severe nationwide shortage of registered nurses forces Tenet to spend billions of dollars on highly expensive temporary 'travel nurses,' severely compressing its profit margins.
The Centers for Medicare and Medicaid Services (CMS) continues to reclassify increasingly complex surgical procedures, such as total joint replacements and advanced spinal fusions, as eligible for outpatient reimbursement, creating a multi-year runway for Tene
Dominant commercial health plans and Medicare Advantage insurers are increasingly utilizing advanced AI-driven prior authorization and denial management tactics to shift financial risk back onto hospitals, systematically compressing Tenet's operating margins a
Factual Scorecard
| Category | Result | Why |
|---|---|---|
| Same-period Revenue Scale | Tenet Healthcare Corporation | $13.6B (FY2025) versus $21.3B (FY2025); the higher figure is identified after approximate USD conversion. |
| Founded Earlier | Tenet Healthcare Corporation | DaVita Inc. was founded in 1979; Tenet Healthcare Corporation was founded in 1969. |
Comparison Takeaway: DaVita vs Tenet Healthcare
Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.
Frequently Asked Questions: DaVita vs Tenet Healthcare
Is DaVita bigger than Tenet Healthcare?
No. Tenet Healthcare reported $21.31 billion in 2025 net operating revenues, about 56% more than DaVita's $13.643 billion for the same fiscal year ended December 31, 2025. Tenet also had more employees, about 99,000 versus DaVita's 78,000.
Which is more profitable, DaVita or Tenet Healthcare?
By net income, Tenet reported $1.407 billion available to common shareholders in 2025 against DaVita's $746.8 million net income attributable to DaVita. Tenet's 2025 figure was boosted by hospital-divestiture gains in prior comparisons, while DaVita's adjusted diluted EPS from continuing operations was $10.78.
Who is the CEO of DaVita and Tenet Healthcare?
Javier J. Rodriguez has been CEO of DaVita since June 1, 2019, succeeding Kent Thiry. Saum Sutaria, M.D. has been Tenet Healthcare's Chairman and CEO since September 1, 2021, after joining Tenet in 2019 as President and COO following nearly two decades at McKinsey.
Does Berkshire Hathaway own DaVita or Tenet Healthcare stock?
Berkshire Hathaway owns about 45% of DaVita, its position since first buying shares in 2011, and a 2024 agreement caps that stake by requiring DaVita to buy back Berkshire's shares as it repurchases stock. Berkshire does not have a comparable disclosed stake in Tenet Healthcare.
Which is bigger for a healthcare investor to compare, DaVita's dialysis model or Tenet's hospital-and-surgery model?
Tenet is the larger, more diversified company at $21.31 billion of 2025 revenue across hospitals, USPI ambulatory surgery centers and Conifer revenue-cycle services. DaVita is a more concentrated $13.643 billion dialysis business whose economics depend heavily on the mix between Medicare's bundled ESRD payment and higher-paying commercial insurers.
Which company was founded first, DaVita Inc. or Tenet Healthcare Corporation?
Tenet Healthcare Corporation was founded in 1969; DaVita Inc. was founded in 1979.
What revenue did DaVita Inc. and Tenet Healthcare Corporation report?
DaVita Inc. had $13.6B (FY2025), while Tenet Healthcare Corporation had $21.3B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.
How do DaVita Inc. and Tenet Healthcare Corporation make money?
DaVita Inc.: DaVita is paid per dialysis treatment. Tenet Healthcare Corporation: Conifer's business model is scalable, relying on a combination of long-term, multi-year enterprise contracts, performance-based fee structures (where Conifer takes a percentage of the additional revenue it recovers for the client), and the licensing of its proprietary analytics and patient engagement software platforms.
Which is better, DaVita Inc. or Tenet Healthcare Corporation?
There is no evidence-based single winner. Compare DaVita Inc. and Tenet Healthcare Corporation on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.
Sources & References
- SEC EDGAR: DaVita Inc. filings search (10-K, 8-K)
- DaVita Inc. Corporate Website
- DaVita Inc. 2025 revenue figure: DAVITA INC. annual report (Form 10-K, SEC EDGAR, filed 2026-02-11)
- sec.gov
- investors.davita.com
- investors.davita.com
- data.sec.gov
- en.wikipedia.org
- SEC EDGAR: Tenet Healthcare Corporation filings search (10-K, 8-K)
- Tenet Healthcare Corporation Corporate Website
- Tenet Healthcare Corporation 2025 revenue figure: TENET HEALTHCARE CORP annual report (Form 10-K, SEC EDGAR, filed 2026-02-17)
- businesswire.com
- businesswire.com
- s23.q4cdn.com
- investor.tenethealth.com
- en.wikipedia.org
Quick Answer
Tenet Healthcare is the bigger company by revenue: $21.31 billion in 2025 net operating revenues versus DaVita's $13.643 billion, both for the fiscal year ended December 31, 2025. Tenet also employed more people, about 99,000 against DaVita's 78,000. DaVita is the more concentrated business, almost entirely dialysis, while Tenet spreads revenue across acute-care hospitals, the USPI ambulatory surgery network and Conifer revenue-cycle services. On profit margin, Tenet's 2025 net income of $1.407 billion was helped by one-time items, while DaVita's $746.8 million came from a steadier, treatment-based business.
Verdict
Tenet is the larger and more diversified of the two, but DaVita is the more capital-return-focused: it carries no dividend and funds buybacks (12.7 million shares repurchased in 2025 at an average $140.09) off $1.024 billion of free cash flow, while Berkshire Hathaway's roughly 45% stake is capped under a 2024 agreement that forces DaVita to keep buying back Berkshire's shares. Tenet's growth engine is USPI, its ambulatory surgery joint-venture platform, which drove Q2 2026 adjusted EBITDA up 16.3% to $1.304 billion company-wide; DaVita's U.S. treatment volume was nearly flat (normalized non-acquired growth of just 0.3% in Q2 2026), so its earnings growth comes mostly from pricing and cost control, with Q2 2026 diluted EPS up 36% year over year. Reimbursement risk differs too: DaVita's economics hinge on the gap between Medicare's bundled ESRD rate and the smaller pool of commercial payers who pay several times more per treatment, while Tenet's hospital segment is exposed to labor-cost inflation and Medicaid/Medicare Advantage denial tactics, offset by USPI's physician-aligned, equity-co-investment model. Tenet is the stronger pick for anyone comparing scale and segment diversification; DaVita is the stronger pick for anyone studying a single-payer-model, buyback-driven healthcare story.
Cite This Page
Automatically generated citations for researchers.
CorpDigest. (2026). DaVita Inc. vs Tenet Healthcare Corporation Comparison. from https://corpdigest.com/compare/davita-vs-tenet-healthcare
CorpDigest. "DaVita Inc. vs Tenet Healthcare Corporation Comparison." CorpDigest, 2026, https://corpdigest.com/compare/davita-vs-tenet-healthcare.
CorpDigest. "DaVita Inc. vs Tenet Healthcare Corporation Comparison." CorpDigest. 2026. https://corpdigest.com/compare/davita-vs-tenet-healthcare.